STL Volume 29 Number 3

STL Volume 29 Number 3
Purchase PDF for $2.79
Intravenous Immunoglobulin Therapy in Dermatology

A Review of the Use of Intravenous Immunoglobulin Therapy in Dermatology

This article reviews the use of intravenous immunoglobulin (IVIG) in dermatology, highlighting its role in treating autoimmune and inflammatory skin diseases. It discusses how IVIG reduces the need for steroids or immunosuppressants and its applications in conditions such as autoimmune bullous dermatoses, dermatomyositis, and Stevens-Johnson syndrome. The article also addresses dosing regimens, potential adverse effects, and the importance of ongoing research to further understand the efficacy and safety of IVIG in dermatologic treatments.
doctor looking at patient's skin

Long-Term Efficacy of Tildrakizumab in the Treatment of Psoriasis

A review of the long-term efficacy and safety of tildrakizumab, a monoclonal antibody targeting the IL-23/IL-17 pathway, in treating moderate-to-severe plaque psoriasis. Evidence from Phase 3 clinical trials and extension studies demonstrates that tildrakizumab is an effective and well-tolerated therapy, significantly improving skin clearance and maintaining a favorable safety profile over several years of use.
image of a doctor operating a diagnostic device

Update on Drugs & Devices: May – June 2024

Update on Mavorixafor capsules (Xolremdi™), Ustekinumab-aekn SC use (Selarsdi™), Spesolimab-sbzo IV/SC use (Spevigo™), LetibotulinumtoxinA-wlbg IM use (Letybo™), and Bimekizumab SC use (Bimzelx®).